Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Avecho Biotechnology Ltd

Company price
0.012 AUD 0.00 ( 20.00%)
Last update at 2026-11-16T04:40:00Z
VOLUME
9741007
Market Cap
38.64M

Momentum Score

…

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avecho Biotechnology Ltd is an Australian-listed biotechnology company that holds and develops biomedical intellectual property; public filings are limited and the company’s programs and stage of development are not extensively documented. Its long-term growth may be driven by successful R&D progress, regulatory approvals or out-licensing, and partnerships that could support commercialization, offering potential milestone-driven upside.
Key investment risks include high development and regulatory uncertainty, limited transparent public information and liquidity, the likely need for additional financing, and strong competition in the biotechnology sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.74M
Revenue Per Share
-
Gross Profit TTM
0.54M
Debt / Equity
0.01
ROE
-268.21%
Net Debt
-4.65M
ROCE
-93.86%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.41M -3.12M -4.51M -2.34M -3.42M
Net income -4.42M -3.12M -3.44M -2.35M -4.57M
Selling general administrative - 1.99M 2.43M 2.26M 2.60M
Selling and marketing expenses - 0.05M 0.83M - -
Gross profit 0.75M 0.67M -0.04M 0.87M 0.51M
Reconciled depreciation - 0.14M 0.18M 0.23M 0.67M
Ebit -6.00M -3.06M -3.42M -2.57M -3.41M
Ebitda -5.87M -2.92M -3.24M -2.34M -2.98M
Depreciation and amortization 0.14M 0.14M 0.18M 0.23M 0.43M
Operating income -6.00M -4.96M -4.59M -2.57M -3.41M
Other operating expenses 7.24M 6.09M 5.06M 4.19M 5.34M
Interest expense 0.46M 0.06M 0.02M 0.01M 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.06M 0.04M 0.00M 0.00M
Net interest income - 0.00M 0.02M -0.00M -0.01M
Income tax expense -2.00M -1.64M -1.08M 0.01M 1.15M
Total revenue 1.24M 1.13M 0.47M 1.21M 0.79M
Total operating expenses 6.76M 5.63M 4.55M 3.93M 5.06M
Cost of revenue 0.49M 0.46M 0.52M 0.34M 0.29M
Total other income expense net -0.41M 1.84M 0.08M 0.22M -0.01M
Net income from continuing ops - -3.12M -3.44M -2.34M -5.15M
Net income applicable to common shares - -3.12M -3.44M -2.34M -3.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.11M 5.00M 7.32M 3.35M 5.25M
Intangible assets - - - 0.03M 0.10M
Other current assets 0.18M 1.73M 0.30M 0.24M 0.22M
Total liab 5.55M 1.73M 0.94M 0.92M 0.71M
Total stockholder equity 1.56M 3.27M 6.38M 2.42M 4.54M
Other current liab 0.59M 0.59M 0.51M 0.48M 0.54M
Common stock 246.90M 244.61M 244.61M 237.53M 237.60M
Capital stock - 244.61M - 237.53M 237.60M
Retained earnings -246.00M -269.39M -239.63M -264.10M -262.07M
Other assets - - 0.00M - -
Cash 4.66M 2.37M 5.50M 1.47M 3.26M
Cash and equivalents - - - 1.47M 3.26M
Total current liabilities 0.71M 1.71M 0.84M 0.75M 0.70M
Current deferred revenue - - 0.16M - -
Net debt -4.65M -1.30M -5.33M -1.22M -3.17M
Short term debt 0.01M 1.06M 0.08M 0.07M 0.08M
Short long term debt - 0.98M - - -
Short long term debt total 0.01M 1.08M 0.18M 0.25M 0.09M
Other stockholder equity - 0.00M - 0.02M 29.00M
Property plant equipment - - - 0.47M 0.34M
Total current assets 7.06M 4.81M 7.00M 2.85M 4.81M
Net tangible assets - - - 2.40M 4.43M
Short term investments - - - 0.09M -
Net receivables 2.20M 0.57M 1.10M 0.75M 1.13M
Inventory 0.01M 0.14M 0.10M 0.40M 0.20M
Accounts payable 0.10M 0.06M 0.09M 0.19M 0.08M
Accumulated other comprehensive income 0.65M 28.06M 1.40M 29.00M 29.00M
Non currrent assets other 0.02M 0.02M -0.00M - -
Non current assets total 0.05M 0.19M 0.32M 0.49M 0.44M
Capital lease obligations - 0.10M - 0.25M 0.09M
Long term debt total - - - 0.18M 0.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M - -0.05M -0.26M
Change to liabilities - - - 0.03M 0.03M
Total cashflows from investing activities - -0.02M 0.00M -0.05M -0.20M
Net borrowings - 0.93M - -0.08M -0.07M
Total cash from financing activities 1.19M 0.85M 7.22M -0.08M 4.69M
Change to operating activities - - - 0.04M 0.04M
Net income -4.42M -3.12M -3.44M -2.35M -5.15M
Change in cash 2.29M -3.13M 4.04M -1.80M 1.39M
Begin period cash flow 2.37M 5.50M 1.47M 3.26M 1.87M
End period cash flow 4.66M 2.37M 5.50M 1.47M 3.26M
Total cash from operating activities 1.10M -3.97M -3.18M -2.27M 0.43M
Issuance of capital stock - - 8.00M 0.00M 5.06M
Depreciation 0.14M 0.14M 0.18M 0.08M 0.43M
Other cashflows from investing activities - -0.02M -0.00M - 0.00M
Change to inventory 0.13M -0.04M -0.06M -0.21M -0.10M
Change to account receivables 0.04M -1.15M -0.35M 0.40M -0.67M
Sale purchase of stock - 0.00M -0.72M 0.00M -0.29M
Other cashflows from financing activities -0.08M -0.08M -0.07M -0.08M -0.07M
Change to netincome - - - 0.18M 0.58M
Capital expenditures 0.00M 0.00M 0.00M 0.05M 0.20M
Change in working capital 4.92M -0.93M -0.39M 1.04M 0.52M
Stock based compensation - 0.01M 0.10M - -
Other non cash items 0.46M -0.07M 0.37M 2.27M 4.73M
Free cash flow 1.10M -3.97M -3.18M -2.33M -0.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVE
Avecho Biotechnology Ltd
0.00
20.00%
0.01 - 4.78 52.40 20.26 43.26 -6.56
CSL
CSL Ltd
-0.40
0.20%
202.52 - 22.73 6.16 4.50 4.84 10.06
TLX
TELIX Pharmaceuticals Ltd
-0.19
1.40%
13.39 90.53 172.41 5.18 6.47 3.91 48.02
NEU
Neuren Pharmaceuticals Ltd
-0.02
0.09%
22.98 153.33 40.32 41.94 8.75 37.82 189.88
MSB
Mesoblast Ltd
-0.04
2.33%
1.89 - 454.55 20.84 3.02 16.59 -9.86

Profile*

Avecho Biotechnology Ltd

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Hallmarc Business Park, Clayton, VIC, Australia, 3168

61 3 9002 5000

Name Title Year Born
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Exec. Officer NA
Dr. Roksan Libinaki Ph.D. Chief Operating Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…